UniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
~ Announced FDA clearance of Investigational New Drug application for AMT-260 in refractory mesial temporal lobe epilepsy ~ ~ On track to provide clinical update from U.S. and European Phase I/II...
Source: marketscreener.com